Literature DB >> 1555645

Direct expression in Escherichia coli and characterization of bovine adrenodoxins with modified amino-terminal regions.

Y Sagara1, T Hara, Y Ariyasu, F Ando, N Tokunaga, T Horiuchi.   

Abstract

Four forms of bovine adrenodoxin with modified amino-termini obtained by direct expression of cDNAs in Escherichia coli are Ad(Met1), Ad(Met-1), Ad(Met-12), and Ad(Met6). The shoulder numbers represent the site of translation initiator Met at the amino-termini. The adrenodoxins, except for Ad(Met-1), were purified from the cell lysate and the ratios of A414-to-A276 of the purified proteins were over 0.92. NADPH-cytochrome c reductase activities of the three forms of adrenodoxin in the presence of adrenodoxin reductase were the same as that of purified bovine adrenocortical adrenodoxin. However, as cytochrome P-450SCC reduction catalyzed by Ad(Met6) was about 60% of that by Ad(Met1), the contribution of the amino-terminal region for the electron transfer or binding to cytochrome P-450SCC would need to be considered.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1555645     DOI: 10.1016/0014-5793(92)80847-a

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

1.  Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.

Authors:  Natalia Mast; Kyle W Anderson; Joseph B Lin; Yong Li; Illarion V Turko; Curtis Tatsuoka; Ingemar Bjorkhem; Irina A Pikuleva
Journal:  J Biol Chem       Date:  2017-02-11       Impact factor: 5.157

2.  Conformational stability of adrenodoxin mutant proteins.

Authors:  T V Burova; V Beckert; H Uhlmann; O Ristau; R Bernhardt; W Pfeil
Journal:  Protein Sci       Date:  1996-09       Impact factor: 6.725

3.  Conversion of 7-ketocholesterol to oxysterol metabolites by recombinant CYP27A1 and retinal pigment epithelial cells.

Authors:  Gun-Young Heo; Ilya Bederman; Natalia Mast; Wei-Li Liao; Illarion V Turko; Irina A Pikuleva
Journal:  J Lipid Res       Date:  2011-03-16       Impact factor: 5.922

4.  Features of the retinal environment which affect the activities and product profile of cholesterol-metabolizing cytochromes P450 CYP27A1 and CYP11A1.

Authors:  Gun-Young Heo; Wei-Li Liao; Illarion V Turko; Irina A Pikuleva
Journal:  Arch Biochem Biophys       Date:  2011-12-29       Impact factor: 4.013

5.  Isotope-Labeling Studies Support the Electrophilic Compound I Iron Active Species, FeO(3+), for the Carbon-Carbon Bond Cleavage Reaction of the Cholesterol Side-Chain Cleavage Enzyme, Cytochrome P450 11A1.

Authors:  Francis K Yoshimoto; I-Ji Jung; Sandeep Goyal; Eric Gonzalez; F Peter Guengerich
Journal:  J Am Chem Soc       Date:  2016-09-12       Impact factor: 15.419

6.  Conformational stability of bovine holo and apo adrenodoxin--a scanning calorimetric study.

Authors:  T V Burova; R Bernhardt; W Pfeil
Journal:  Protein Sci       Date:  1995-05       Impact factor: 6.725

7.  Mutational analysis of CYP27A1: assessment of 27-hydroxylation of cholesterol and 25-hydroxylation of vitamin D.

Authors:  Ram P Gupta; Kennerly Patrick; Norman H Bell
Journal:  Metabolism       Date:  2007-09       Impact factor: 8.694

8.  Drugs and Scaffold That Inhibit Cytochrome P450 27A1 In Vitro and In Vivo.

Authors:  Morrie Lam; Natalia Mast; Irina A Pikuleva
Journal:  Mol Pharmacol       Date:  2017-11-30       Impact factor: 4.436

9.  Inhibition and stimulation of activity of purified recombinant CYP11A1 by therapeutic agents.

Authors:  Natalia Mast; Marlin Linger; Irina A Pikuleva
Journal:  Mol Cell Endocrinol       Date:  2012-10-23       Impact factor: 4.102

10.  N,N-Dimethyl-3β-hydroxycholenamide Reduces Retinal Cholesterol via Partial Inhibition of Retinal Cholesterol Biosynthesis Rather Than its Liver X Receptor Transcriptional Activity.

Authors:  Nicole El-Darzi; Artem Astafev; Natalia Mast; Aicha Saadane; Morrie Lam; Irina A Pikuleva
Journal:  Front Pharmacol       Date:  2018-07-25       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.